Newsfile Corp
05 Jun 2026, 21:35 UTC · 2h ago
Charlotte's Web Announces Board Transition as Co-Founder Jared Stanley Deepens Focus on DeFloria
Newsfile Corp
05 Jun 2026, 21:35 UTC · 2h ago
Story key points
3 claims · impact-rated
DeFloria, a company co-founded by Charlotte's Web, is advancing AJA001 oral solution through FDA Phase 2 clinical trials for autism-related irritability. — Successful progression of a clinical-stage pharmaceutical drug creates a high-value catalyst and potential new revenue stream beyond consumer wellness.
+0.60Charlotte's Web maintains a direct equity stake in DeFloria and provides the proprietary full-spectrum hemp genetics used in the AJA001 drug. — This ensures Charlotte's Web captures the upside of DeFloria's clinical success and validates the quality of its genetic intellectual property.
+0.30Co-founder Jared Stanley has stepped down from Charlotte's Web's Board of Directors to focus exclusively as CEO of DeFloria. — The loss of a founding member from the board is generally a slight negative for governance stability, though mitigated by his continued advisory role.
-0.20Ticker attribution
Continue reading
6 related stories
Top 3 movers · tap to explore
Model heads
The company maintains a strategic stake in DeFloria's clinical progress and benefits from favorable regulatory tailwinds for cannabinoids.
British American Tobacco is a lead investor in DeFloria, which is advancing a botanical drug through FDA Phase 2.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
1 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
MarketBeat
14h ago
